Biotricity Bilan de santé

Santé financière contrôle des critères 0/6

Biotricity possède un total de capitaux propres de $-27.2M et une dette totale de $21.8M, ce qui porte son ratio d'endettement à -80.2%. Son actif total et son passif total sont $5.3M et de $32.5M.

Informations clés

-80.2%

Ratio d'endettement

US$21.84m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$746.94k
Fonds propres	-US$27.23m
Total du passif	US$32.52m
Total des actifs	US$5.29m

Mises à jour récentes de la santé financière

Recent updates

Analyse de la situation financière

Passif à court terme: BTCY a des fonds propres négatifs, ce qui est une situation plus grave que des actifs à court terme ne couvrant pas les passifs à court terme.

Passif à long terme: BTCY a des capitaux propres négatifs, ce qui est une situation plus grave que des actifs à court terme ne couvrant pas les passifs à long terme.

Historique et analyse du ratio d'endettement

Niveau d'endettement: BTCY a des fonds propres négatifs, ce qui est une situation plus grave qu'un niveau d'endettement élevé.

Réduire la dette: BTCY a des capitaux propres négatifs, nous n'avons donc pas besoin de vérifier si sa dette a diminué au fil du temps.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: BTCY dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: BTCY dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 7.3 % chaque année

Biotricity Bilan de santé

Santé financière contrôle des critères 0/6

Informations clés

Mises à jour récentes de la santé financière

Biotricity, Inc. announced delayed 10-Q filing

Biotricity, Inc. Receives Non-Compliance Letter from Nasdaq Regarding Bid Price Rule

Nasdaq Notifies Biotricity That the Nasdaq Hearings Panel Grants Its Request to Continue Its Listing on Nasdaq

Biotricity, Inc. announced delayed 10-Q filing

Biotricity, Inc. Receives A Delisting Determination Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Biotricity Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Market Value of Listed Securities Requirement

Recent updates

Biotricity Kicks Off Another Pilot Program with A Major Hospital System That Services over 800,000 Individuals

Biotricity, Inc. announced delayed 10-Q filing

Biotricity, Inc. Receives Non-Compliance Letter from Nasdaq Regarding Bid Price Rule

Biotricity, Inc., Annual General Meeting, Aug 15, 2024

Biotricity Adds 60-Site, Multi-State Hospital Cardiac Monitoring Pilot Program

Biotricity, Inc. Launches Direct-To-Consumer Heart Health Screening Service, Heartsecure, Making Heart Health Services

Biotricity, Inc. has filed a Follow-on Equity Offering in the amount of $2.684644 million.

Biotricity Inc. Announces High Demand for Its Latest Device, Biotres Pro

Biotricity, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.55 million.

Nasdaq Notifies Biotricity That the Nasdaq Hearings Panel Grants Its Request to Continue Its Listing on Nasdaq

Biotricity, Inc. announced that it has received $2 million in funding

Biotricity Announces Strategic Partnership for Cardiac Screenings in Patients with Co-Morbidities

Biotricity, Inc. announced a financing transaction

Biotricity Unveils That Improved Margins Resulted from Latest Advancements to Its Proprietary Cardiac Ai Cloud Platform and Announces Plans for Continued Expansion of Its Cardiac AI Cloud

Biotricity, Inc. has filed a Follow-on Equity Offering in the amount of $10.55 million.

Biotricity, Inc. has filed a Follow-on Equity Offering in the amount of $10.55 million.

Biotricity, Inc. announced delayed 10-Q filing

Biotricity, Inc. Receives A Delisting Determination Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Investors Give Biotricity, Inc. (NASDAQ:BTCY) Shares A 38% Hiding

Biotricity Inc. Expands Development of its Cardiac AI Cloud Platform with Data Ecosystem of over 360 Billion Heartbeats

New major risk - Share price stability

Second quarter 2024 earnings released: US$0.44 loss per share (vs US$0.57 loss in 2Q 2023)

Biotricity, Inc. to Report Q2, 2024 Results on Nov 14, 2023

Biotricity Releases Another Groundbreaking Product: Biotres Pro

New major risk - Market cap size

Many Still Looking Away From Biotricity, Inc. (NASDAQ:BTCY)

Biotricity Continues to Expand Patent Portfolio with Latest Patent Filing for Bioheart Device

Biotricity, Inc. Announces Patent Filing for Cutting-Edge Biotres Device

Biotricity, Inc. has completed a Follow-on Equity Offering.

New major risk - Financial position

First quarter 2024 earnings released: US$0.069 loss per share (vs US$0.59 loss in 1Q 2023)

Biotricity Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Market Value of Listed Securities Requirement

Biotricity Inc. Expands Its Proprietary AI Model and Deepens Relationship with Amazon Aws and Google's Tensor Flow for Remote Cardiac Care Applications

Biotricity Regains Nasdaq Listing Compliance

Biotricity, Inc. Provides Earnings Guidance for the First Fiscal Quarter Ended June 30, 2023

Full year 2023 earnings released: US$0.38 loss per share (vs US$0.67 loss in FY 2022)

Third quarter 2023 earnings: Revenues exceed analyst expectations

Biotricity Receives A Letter from Nasdaq Capital Market Regarding Minimum Bid Price

Consensus revenue estimates fall by 19%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$3.83

Less than half of directors are independent

Biotricity, Inc. Launches Cardiac Disease Management Solution Following 2 Successful Pilots with Oklahoma & Kentucky Clinics

Less than half of directors are independent

Biotricity GAAP EPS of -$0.09, revenue of $2.06M

Biotricity Announces Management Changes

Biotricity, Inc.: A First Take

Biotricity, Inc. announced delayed annual 10-K filing

Is Biotricity (NASDAQ:BTCY) Using Debt In A Risky Way?

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Biotricity, Inc. to Report Q3, 2022 Results on Feb 14, 2022

High number of new directors

Does Biotricity (NASDAQ:BTCY) Have A Healthy Balance Sheet?

High number of new directors

Biotricity: Capital Raise Leads To Buying Opportunity

Biotricity Common Stock Deleted from Other OTC

Biotricity, Inc. announced delayed 10-Q filing

Biotricity, Inc. Announces Earnings Guidance for the Fiscal 2022

Biotricity, Inc. to Report Q3, 2021 Results on Feb 11, 2021

Biotricity, Inc. announced that it has received $9.5575 million in funding

Biotricity Announces New Solution for Personal Heart Management with Bioheart

Biotricity, Inc. Prepares 510(k) FDA Filing for Biotres

Biotricity Inc. Announces Launch of Its Bioflux® Direct Program

Biotricity, Inc. announced a financing transaction

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines